Navigation Links
ORYZON to Present at Rodman & Renshaw 17th Annual Global Investment Conference
Date:8/27/2015

BARCELONA, Spain and CAMBRIDGE, Mass., Aug. 27, 2015 /PRNewswire/ -- Oryzon today announced that it will be presenting at the Rodman & Renshaw 17th Annual Global Investment Conference in New York City. Held at the St. Regis Hotel, ORYZON will be represented by President and CEO Carlos Buesa.

Dr. Buesa will present this information on Thursday September 10, 2:10 to 2:35 pm EDT, at the Fontainebleau Room (2nd Floor).  The company is completing preclinical development of its ORY-2001 epigenetics molecule targeting Alzheimer's Disease. The molecule is expected to enter Phase I clinical development early next year. In April 2014 ORYZON closed a global licensing collaboration with ROCHE on its first asset, ORY-1001 a LSD1 inhibitor for the treatment of leukemia and other malignancies, currently in Phase I/IIA. Under the terms of the agreement, Oryzon received an upfront payment and near-term milestones totaling $21 million, plus potential development, commercial and sales milestone payments across haematology, cancer and non-malignant indications that could exceed $500 million, together with tiered sales royalties. During the Conference, the company will hold private meetings with specialized funds and with US investment banks.

Oryzon's drug candidates target the enzyme LSD1, a histone demethylase which plays a role in regulating the expression of crucial genes that neurons need to stay alive. LSD1 is able to switch the expression of those genes on and off in the neurons in response to age, insults and environmental conditions. LSD1 also regulates the expression of genes involved in the progression of AD and other neurological disorders, such as Parkinson´s and Huntington's diseases. 

The Rodman & Renshaw 17th Annual Global Investment Conference includes over 200 public and private companies presenting their businesses to an audience of approximately 2,000 attendees. With tracks dedicated to Healthcare, Metals & Mining, Technology, Cleantech and Growth, this year's conference will bring presenting companies together with a vast audience of financial and strategic investors.  In addition to corporate presentations, Rodman facilitates one-on-one investor meetings and provides platforms for engaged Q&A sessions. Rodman & Renshaw is proud to donate a portion of proceeds from this year's event to New York University's Center for Neural Science. This year, the Conference will be opened by the keynote speaker Dr. Henry A. Kissinger, 56th United States Secretary of State.

ABOUT ORYZON

Founded in 2000 in Barcelona, Spain, Oryzon (www.oryzon.com) is a privately held, clinical stage biopharmaceutical company considered as the European champion in Epigenetics with one of the strongest portfolio in the field. Its LSD1 program is currently covered by 19 patent families and has rendered one compound in clinical trials and another one to enter clinical trials in 2016. In addition, Oryzon has ongoing programs for developing inhibitors against other histone demethylases and histone methyltransferases. The company has a strong technological platform for biomarker identification and performs biomarker and target validation for a variety of malignant and neurodegenerative diseases. Oryzon's strategy is to develop first in class compounds against novel epigenetic targets through Phase II clinical trials, at which point we decide on a case-by-case basis to either continue development in-house or to partner or out-license the compound for late stage development and commercialization.  In October 2014, ORYZON announced opening of U.S. operations in Cambridge, Massachusetts through its U.S. affiliate, Oryzon Corp.

CONTACTS:

Carlos Buesa                                                                                     
President & CEO                                            
Email

Emili Torrell     
Business Development Officer                 
Email

ATREVIA 
Ana Melgar 
Email 
Telephone/Spain: 915 640 725


'/>"/>
SOURCE Oryzon
Copyright©2015 PR Newswire.
All rights reserved

Related medicine technology :

1. SciClone To Present At Two Investor Conferences On September 10, 2015
2. Lexicon Announces Telotristat Etiprate Data To Be Presented At European Cancer Congress
3. Henry Schein To Present At Three Investor Conferences In September
4. DelMar Pharmaceuticals to Present at the 17th Annual Rodman & Renshaw Global Investment Conference on September 9, 2015
5. PDA Presents its Perspective on the US FDA Quality Metrics Draft Guidance at Public Meeting
6. Mirati Therapeutics To Present Preclinical And Clinical Data At The IASLC 16th World Conference On Lung Cancer
7. Misonix to Present at the Sidoti Emerging Growth Conference
8. Rock Creek Pharmaceuticals to Present at the Annual BioPharm America International Partnering Conference
9. Trovagene to Present Clinical Data and Capabilities of Its Urine-Based Liquid Biopsy Platform at the 7th Annual Next Generation Dx Summit
10. Instrumentation Review 2015 - Presents Strategic Assessments of Current and Emerging Suppliers
11. Rock Creek Pharmaceuticals to Present at the 17th Annual Rodman & Renshaw Global Investment Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/30/2021)... ... March 29, 2021 , ... The University of Texas Health Science Center ... San Antonio Multispecialty and Research Hospital, a destination center for research and treatment of ... In a nod to the COVID-19 pandemic, the ceremony was held virtually. , William ...
(Date:3/30/2021)... ... March 29, 2021 , ... Iora Health ... primary care, has partnered with Devoted Health , one of the fastest-growing ... across Maricopa County and provides seniors with the highest-quality care and experience possible, ...
(Date:3/30/2021)... CITY (PRWEB) , ... March 29, 2021 , ... ... has joined the Vaccine Credential Initiative (VCI), a group bringing together leading health ... record of vaccination status, based on open, interoperable standards. By joining the VCI ...
Breaking Medicine Technology:
(Date:3/30/2021)... , ... March 29, 2021 , ... ... the 21st Century , A Virtual Workshop Presented by WCG FDAnews and Cerulean ... 4:30 pm EDT, https://wcg.swoogo.com/modern-sop-and-quality-systems , Are one’s SOPs written for the ...
(Date:3/30/2021)... ... March 29, 2021 , ... According to data released ... reproductive age (13-44) in need of publicly funded contraception live in counties impacted by ... Colorado’s 64 counties have lost some of their Title X resources. , The ...
(Date:3/30/2021)... ... March 29, 2021 , ... Health Literacy Innovations (HLI), a ... confusion due to low health literacy today announces a new partnership with the ... work with ACAP’s member Safety Net Health Plans, those that provide comprehensive health ...
(Date:3/30/2021)... ... ... Dr. Colin Campbell is proud to announce the 1 year anniversary in their new state ... internal medicine and is a primary care specialist who has been practicing for 23 years. ... keep South Jersey healthy one patient at a time. , “Over the past year, Dr. ...
(Date:3/30/2021)... ... March 30, 2021 , ... The COVID-19 ... and survivors; their families; and their caregivers. Crossroads4Hope is addressing the needs of ... emotional support system, MyGo2Support, which meets needs of people impacted by cancer, no ...
Breaking Medicine News(10 mins):